GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a blockbuster heartburn drug.

GSK faces whistleblower lawsuit over Zantac cancer risk

Haleon PLC

GSK PLC (LSE:GSK, NYSE:GSK) confirmed it has raised a total of £3.9 billion through the exit of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), the healthcare firm which was spun out by the pharma giant back in 2022. On Friday, the Brentford-based firm revealed it raised £1.24 billion after it sold the final part of its stake in Haleon, offloading more than 385 million shares at 324p each.

GSK confirms exit of Haleon stake for £3.9 billion

GSK has raised 1.25 billion pounds ($1.52 billion) from selling its entire remaining stake in consumer healthcare firm Haleon, the British drugmaker said on Friday.

GSK raises $1.5 bln from offloading Haleon stake at a discount

British drugmaker GSK said on Thursday it plans to sell about 385 million shares, representing its entire shareholding, in spun-off consumer healthcare business Haleon.

GSK intends to sell its remaining stake in Haleon

BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant ("MDR") bacteria, announced today the expansion of its strategic collaboration with the global biopharma company GSK plc (LSE/NYSE: GSK) to accelerate the clinical development of alpibectir (BVL-GSK098) for the treatment of tuberculosis (TB).

BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million

This covered call equates to a 6.26% return, or 22.17% on an annualized basis.

GSK Stock Today: Buying An August Covered Call Boosts Your Return By This Much

GSK plc (NYSE:GSK ) Q1 2024 Earnings Conference Call May 1, 2024 3:00 AM ET Company Participants Nick Stone - Head of Investor Relations Emma Walmsley - Chief Executive Officer Luke Miels - Chief Commercial Officer Deborah Waterhouse - Chief Executive Officer, ViiV Healthcare Julie Brown - Chief Financial Officer Tony Wood - Chief Scientific Officer Conference Call Participants Mark Purcell - Morgan Stanley Kerry Holford - Joh. Berenberg, Gossler & Co. Graham Parry - Bank of America Merrill Lynch Jo Walton - UBS Stephen Scala - TD Cowen Simon Baker - Redburn Atlantic James Gordon - JPMorgan Emily Field - Barclays Bank PLC Richard Parkes - BNP Paribas Peter Verdult - Citigroup Inc. Peter Welford - Jefferies LLC Timothy Anderson - Wolfe Research, LLC Nick Stone Hello everyone.

GSK plc (GSK) Q1 2024 Earnings Call Transcript

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why GSK (GSK) is a Top Growth Stock for the Long-Term

Apple

Advanced Micro Devices

Alphabet

Mitsubishi Electric Corp

NVIDIA

Yesterday, the biggest company in the world in terms of market cap reported its latest earnings. But Apple Inc. is far from the only blue chip stock around.

5 best blue chip stocks to invest in for sustainable gains in May – excluding Apple Inc. (AAPL)

U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

Affirm

Dominion Energy

Innovative Industrial Properties

Kaiser Aluminum

Organon & Co

Sunoco

Sleeper stocks to buy – based on Nasdaq.com's glossary – represent securities that offer significant price appreciation potential once its fundamentals have been recognized. That could cover a lot of enterprises so I decided to narrow down the list.

7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024

GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.

GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance

GSK (GSK) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $0.90 per share a year ago.

GSK (GSK) Q1 Earnings and Revenues Surpass Estimates

GSK PLC (LSE:GSK, NYSE:GSK) is approaching 18-month highs after the pharma group's boss Emma Walmsley raised the full-year outlook on the back of strong first-quarter results, with analysts saying performances are starting to allay long-held concerns. The shares rose 2.2% to £17.10 on Wednesday morning, within touching distance of the £17.25 highs earlier this year but still some way from pandemic highs towards £19 and all-time peaks above £20 in the dotcom era.

GSK beginning to alleviate long-held concerns, say analysts

GSK PLC (LSE:GSK, NYSE:GSK) has confirmed what recent prescription data hinted at: Its vaccines business is firing on all cylinders. Bumper sales of jabs for shingles and the cold-like condition RSV were the propellants behind better-than-expected numbers from the pharma giant.

GSK Q1 beats consensus and FY numbers upgraded after vaccines boost

GSK raised its full-year profit forecast on Wednesday, betting on strong demand for its common respiratory virus and shingles vaccines.

GSK raises full-year profit forecast

AstraZeneca

Novo Nordisk

Teva Pharmaceutical

The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like Novo Nordisk's diabetes drug Ozempic by making it harder to produce generic drugs.

FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How

AbbVie

WASHINGTON — Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.

FTC challenges ‘bogus' patents on Ozempic, other drugs that ‘block competition'

WisdomTree India Earnings Fund

GE Vernova LLC

Few experts expect the U.S. Federal Reserve to raise interest rates this year. And Fed Chairman Jerome Powell still has not ruled out the possibility of the central bank cutting rates in 2024.

Forget the Fed. These 3 Stocks Will Soar No Matter What

In the most recent trading session, GSK (GSK) closed at $40.91, indicating a +0.12% shift from the previous trading day.

Why the Market Dipped But GSK (GSK) Gained Today

BioNTech SE

Pfizer

GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines.

GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK (GSK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.

GSK Gears Up for Q1 Earnings: Here's What to Expect

The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.

GSK Announces FDA Acceptance of New Meningococcal Jab BLA

GSK has delivered encouraging updates from ongoing trials of its vaccines for Shingles and Gonorrhoea. In the follow-up Zoster trial for the now on-sale Shingrix vaccine, efficacy was more than 80% for patients over 50 between 6-11 years after the jab with no new safety issues identified.

GSK encouraged by Shingles and Gonorrhoea trials

News for GlaxoSmithKline Stock (GSK)